Repros Therapeutics Inc. (Nasdaq: RPRX) received a Complete Response Letter from the Food and Drug Administration for its secondary hypogonadism treatment enclomiphene sending the stock price plummeting 66 cents to close at $1.74.
FDA issues CRL to Repros Therapeutics
December 01, 2015 at 16:41 PM EST